Trials / Recruiting
RecruitingNCT06946797
A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)
A Phase 2, Open-label, Randomized Trial to Evaluate Two Dosing Regimens of Subcutaneous Formulation of Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent NSCLC
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 76 (estimated)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate two dosing regimens of subcutaneous Nivolumab in combination with intravenous Ipilimumab and chemotherapy in participants with previously untreated metastatic or recurrent Non-Small Cell Lung Cancer (NSCLC)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Nivolumab | Specified dose on specified days |
| DRUG | Ipilimumab | Specified dose on specified days |
| DRUG | Carboplatin | Specified dose on specified days |
| DRUG | Paclitaxel | Specified dose on specified days |
| DRUG | Pemetrexed | Specified dose on specified days |
| DRUG | Cisplatin | Specified dose on specified days |
Timeline
- Start date
- 2025-09-19
- Primary completion
- 2027-02-05
- Completion
- 2028-10-25
- First posted
- 2025-04-27
- Last updated
- 2026-04-15
Locations
48 sites across 11 countries: United States, Brazil, Chile, France, Greece, Italy, Mexico, Poland, Romania, South Africa, Turkey (Türkiye)
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06946797. Inclusion in this directory is not an endorsement.